{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:13:43Z","timestamp":1776471223693,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Exp Biol Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10517-025-06444-5","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:00:59Z","timestamp":1752904859000},"page":"112-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cell Therapy for Type 1 Diabetes Mellitus: a Review of Clinical Trials"],"prefix":"10.1007","volume":"179","author":[{"given":"M. I.","family":"Danilevskii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. V.","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. N.","family":"Skaletskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu. B.","family":"Basok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Roumiantsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Lyundup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"6444_CR1","doi-asserted-by":"publisher","unstructured":"Laptev DN, Dedov II. Towards prevention of type 1 diabetes: FDA approved first drug with potential to delay clinical stage of disease. Diabetes Mellitus. 2022;25(6):576-9. Russian. https:\/\/doi.org\/10.14341\/DM12988","DOI":"10.14341\/DM12988"},{"key":"6444_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","volume":"383","author":"MA Atkinson","year":"2014","unstructured":"Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69-82. https:\/\/doi.org\/10.1016\/S0140-6736(13)60591-7","journal-title":"Lancet."},{"key":"6444_CR3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449-62. https:\/\/doi.org\/10.1016\/S0140-6736(18)31320-5","journal-title":"Lancet."},{"key":"6444_CR4","doi-asserted-by":"publisher","unstructured":"Dedov I, Shestakova M, Mayorov A, et al. Standards of specialized diabetes care. Dedov II, Shestakova MV, Mayorov AYu, eds. 11th edition. Diabetes Mellitus. 2023; 26(2S):1-157. Russian. https:\/\/doi.org\/10.14341\/DM13042","DOI":"10.14341\/DM13042"},{"issue":"5","key":"6444_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00125-021-05398-3","volume":"64","author":"BJ von Scholten","year":"2021","unstructured":"von Scholten BJ, Kreiner FF, Gough SCL, et al. Current and future therapies for type 1 diabetes. Diabetologia. 2021;64(5):1037-48. https:\/\/doi.org\/10.1007\/s00125-021-05398-3","journal-title":"Diabetologia."},{"issue":"5","key":"6444_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037004","volume":"7","author":"TC Schulz","year":"2012","unstructured":"Schulz TC, Young HY, Agulnick AD, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One. 2012;7(5):e37004. https:\/\/doi.org\/10.1371\/journal.pone.0037004","journal-title":"PLoS One."},{"issue":"8","key":"6444_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.5966\/sctm.2015-0058","volume":"4","author":"TC Schulz","year":"2015","unstructured":"Schulz TC. Concise review: manufacturing of pancreatic endoderm cells for clinical trials in type 1 diabetes. Stem Cells Transl Med. 2015;4(8):927-31. https:\/\/doi.org\/10.5966\/sctm.2015-0058","journal-title":"Stem Cells Transl Med."},{"issue":"12","key":"6444_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100466","volume":"2","author":"AMJ Shapiro","year":"2021","unstructured":"Shapiro AMJ, Thompson D, Donner TW, et al. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep Med. 2021;2(12):100466. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100466","journal-title":"Cell Rep Med."},{"issue":"12","key":"6444_CR9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.stem.2021.10.003","volume":"28","author":"A Ramzy","year":"2021","unstructured":"Ramzy A, Thompson DM, Ward-Hartstonge KA, et al. Implanted pluripotent stemcell-derived pancreatic endoderm cells secrete glucoseresponsive C-peptide in patients with type 1 diabetes. Cell Stem Cell. 2021;28(12):2047-61.e5. https:\/\/doi.org\/10.1016\/j.stem.2021.10.003","journal-title":"Cell Stem Cell."},{"issue":"8","key":"6444_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse GG, Hirata RK, Funk SE, et al. HLAE-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765-72. https:\/\/doi.org\/10.1038\/nbt.3860","journal-title":"Nat Biotechnol."},{"issue":"5","key":"6444_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gt.2015.18","volume":"22","author":"MM El Khatib","year":"2015","unstructured":"El Khatib MM, Sakuma T, Tonne JM, et al. \u03b2-cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. Gene Ther. 2015;22(5):430-8. https:\/\/doi.org\/10.1038\/gt.2015.18","journal-title":"Gene Ther."},{"issue":"Pt 5","key":"6444_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1042\/BST0360963","volume":"36","author":"A Shalev","year":"2008","unstructured":"Shalev A. Lack of TXNIP protects beta-cells against glucotoxicity. Biochem Soc Trans. 2008;36(Pt 5):963-5. https:\/\/doi.org\/10.1042\/BST0360963","journal-title":"Biochem Soc Trans."},{"issue":"21","key":"6444_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131028","volume":"4","author":"NW Zammit","year":"2019","unstructured":"Zammit NW, Walters SN, Seeberger KL, et al. A20 as an immune tolerance factor can determine islet transplant outcomes. JCI Insight. 2019;4(21):e131028. https:\/\/doi.org\/10.1172\/jci.insight.131028","journal-title":"JCI Insight."},{"issue":"2","key":"6444_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.celrep.2014.03.023","volume":"7","author":"M Lindahl","year":"2014","unstructured":"Lindahl M, Danilova T, Palm E, et al. MANF is indispensable for the proliferation and survival of pancreatic \u03b2 cells. Cell Rep. 2014;7(2):366-75. https:\/\/doi.org\/10.1016\/j.celrep.2014.03.023","journal-title":"Cell Rep."},{"issue":"7","key":"6444_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490-500. https:\/\/doi.org\/10.1038\/nri2785","journal-title":"Nat Rev Immunol."},{"issue":"2","key":"6444_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302-16. https:\/\/doi.org\/10.1016\/j.immuni.2019.01.020","journal-title":"Immunity."},{"key":"6444_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi S, Mikami N, Wing JB, et al. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38:541-66. https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041717","journal-title":"Annu Rev Immunol."},{"issue":"3","key":"6444_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1572","volume":"9","author":"Q Tang","year":"2008","unstructured":"Tang Q, Bluestone JA. The Foxp3+ regulatory T-cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9(3):239-44. https:\/\/doi.org\/10.1038\/ni1572","journal-title":"Nat Immunol."},{"issue":"11","key":"6444_CR19","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1084\/jem.20040139","volume":"199","author":"Q Tang","year":"2004","unstructured":"Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455-65. https:\/\/doi.org\/10.1084\/jem.20040139","journal-title":"J Exp Med."},{"key":"6444_CR20","doi-asserted-by":"publisher","unstructured":"Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189. https:\/\/doi.org\/10.1126\/scitranslmed.aad4134","DOI":"10.1126\/scitranslmed.aad4134"},{"issue":"18","key":"6444_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147474","volume":"6","author":"S Dong","year":"2021","unstructured":"Dong S, Hiam-Galvez KJ, Mowery CT, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021;6(18):e147474. https:\/\/doi.org\/10.1172\/jci.insight.147474","journal-title":"JCI Insight."},{"issue":"4","key":"6444_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJM200007273430401","volume":"343","author":"AM Shapiro","year":"2000","unstructured":"Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230-8. https:\/\/doi.org\/10.1056\/NEJM200007273430401","journal-title":"N Engl J Med."},{"key":"6444_CR23","doi-asserted-by":"publisher","unstructured":"Bender C, Wiedeman AE, Hu A, et al. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Sci Transl Med. 2024;16(746):eadn2404. https:\/\/doi.org\/10.1126\/scitranslmed.adn2404","DOI":"10.1126\/scitranslmed.adn2404"},{"key":"6444_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fimmu.2017.01279","volume":"8","author":"BE Phillips","year":"2017","unstructured":"Phillips BE, Garciafigueroa Y, Trucco M, et al. Clinical tolerogenic dendritic cells: exploring therapeutic impact on human autoimmune disease. Front Immunol. 2017;8:1279. https:\/\/doi.org\/10.3389\/fimmu.2017.01279","journal-title":"Front Immunol."},{"issue":"10","key":"6444_CR25","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1172\/JCI43522","volume":"120","author":"H Jiang","year":"2010","unstructured":"Jiang H, Canfield SM, Gallagher MP, et al. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest. 2010;120(10):3641-50. https:\/\/doi.org\/10.1172\/JCI43522","journal-title":"J Clin Invest."},{"key":"6444_CR26","doi-asserted-by":"publisher","unstructured":"Gaglia JL, Daley H, Kayton Bryant N, et al. 825-P: Novel autologous dendritic cell therapy AVT001 for type 1 diabetes. Diabetes. 2023;72(Suppl 1). https:\/\/doi.org\/10.2337\/db23-825-p","DOI":"10.2337\/db23-825-p"},{"key":"6444_CR27","doi-asserted-by":"publisher","first-page":"1054968","DOI":"10.3389\/fimmu.2022.1054968","volume":"13","author":"T Nikolic","year":"2022","unstructured":"Nikolic T, Suwandi JS, Wesselius J, et al. Tolerogenic dendritic cells pulsed with islet antigen induce longterm reduction in T-cell autoreactivity in type 1 diabetes patients. Front Immunol. 2022;13:1054968. https:\/\/doi.org\/10.3389\/fimmu.2022.1054968","journal-title":"Front Immunol."},{"issue":"9","key":"6444_CR28","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dc11-0472","volume":"34","author":"N Giannoukakis","year":"2011","unstructured":"Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34(9):2026-32. https:\/\/doi.org\/10.2337\/dc11-0472","journal-title":"Diabetes Care."},{"issue":"2","key":"6444_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","volume":"18","author":"J Galipeau","year":"2016","unstructured":"Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151-9. https:\/\/doi.org\/10.1016\/j.jcyt.2015.11.008","journal-title":"Cytotherapy."},{"issue":"10","key":"6444_CR30","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","volume":"21","author":"S Viswanathan","year":"2019","unstructured":"Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019-24. https:\/\/doi.org\/10.1016\/j.jcyt.2019.08.002","journal-title":"Cytotherapy."},{"issue":"8","key":"6444_CR31","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00125-023-05934-3","volume":"66","author":"PO Carlsson","year":"2023","unstructured":"Carlsson PO, Espes D, Sisay S, et al. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I\/II randomised double-blind placebo-controlled trial. Diabetologia. 2023;66(8):1431-41. https:\/\/doi.org\/10.1007\/s00125-023-05934-3","journal-title":"Diabetologia."},{"key":"6444_CR32","doi-asserted-by":"publisher","unstructured":"Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. https:\/\/doi.org\/10.1080\/14653240600855905","DOI":"10.1080\/14653240600855905"},{"key":"6444_CR33","doi-asserted-by":"publisher","unstructured":"Izadi M, Sadr Hashemi Nejad A, Moazenchi M, et al. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebocontrolled clinical trial. Stem Cell Res Ther. 2022;13(1):264. https:\/\/doi.org\/10.1186\/s13287-022-02941-w","DOI":"10.1186\/s13287-022-02941-w"},{"issue":"13","key":"6444_CR34","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.yexcr.2006.04.008","volume":"312","author":"Y Zhao","year":"2006","unstructured":"Zhao Y, Wang H, Mazzone T. Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res. 2006;312(13):2454-64. https:\/\/doi.org\/10.1016\/j.yexcr.2006.04.008","journal-title":"Exp Cell Res."},{"issue":"5","key":"6444_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103058","volume":"21","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Knight CM, Jiang Z, et al. Stem Cell educator therapy in type 1 diabetes: from the bench to clinical trials. Autoimmun Rev. 2022;21(5):103058. https:\/\/doi.org\/10.1016\/j.autrev.2022.103058","journal-title":"Autoimmun Rev."},{"key":"6444_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1741-7015-10-3","volume":"10","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Jiang Z, Zhao T, et al. Reversal of type 1 diabetes via islet \u03b2 cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012;10:3. https:\/\/doi.org\/10.1186\/1741-7015-10-3","journal-title":"BMC Med."},{"issue":"12","key":"6444_CR37","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.ebiom.2015.11.003","volume":"2","author":"E Delgado","year":"2015","unstructured":"Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, et al. Modulation of autoimmune T-cell memory by stem cell educator therapy: phase 1\/2 clinical trial. EBioMedicine. 2015;2(12):2024-36. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.003","journal-title":"EBioMedicine."},{"issue":"8","key":"6444_CR38","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/sctm.17-0078","volume":"6","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Jiang Z, Delgado E, et al. Platelet-derived mitochondria display embryonic stem cell markers and improve pancreatic islet \u03b2-cell function in humans. Stem Cells Transl Med. 2017;6(8):1684-97. https:\/\/doi.org\/10.1002\/sctm.17-0078","journal-title":"Stem Cells Transl Med."}],"container-title":["Bulletin of Experimental Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10517-025-06444-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10517-025-06444-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10517-025-06444-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:06:29Z","timestamp":1753419989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10517-025-06444-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6444"],"URL":"https:\/\/doi.org\/10.1007\/s10517-025-06444-5","relation":{},"ISSN":["0007-4888","1573-8221"],"issn-type":[{"value":"0007-4888","type":"print"},{"value":"1573-8221","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}